|
Human Gene Therapy
Coexpression of Tyrosine Hydroxylase, GTP Cyclohydrolase I, Aromatic Amino Acid Decarboxylase, and Vesicular Monoamine Transporter 2 from a Helper Virus-Free Herpes Simplex Virus Type 1 Vector Supports High-Level, Long-Term Biochemical and Behavioral Correction of a Rat Model of Parkinson's Disease
To cite this article:
Mei Sun, Lingxin Kong, Xiaodan Wang, Courtney Holmes, Qingsheng Gao, Guo-Rong Zhang, Josef Pfeilschifter, David S. Goldstein, Alfred I. Geller.
Human Gene Therapy.
December 2004,
15(12): 1177-1196.
doi:10.1089/hum.2004.15.1177.
Mei Sun Department of Neurology, West Roxbury VA Hospital/Harvard Medical School, West Roxbury, MA 02132. Lingxin Kong Department of Neurology, West Roxbury VA Hospital/Harvard Medical School, West Roxbury, MA 02132. Xiaodan Wang Department of Neurology, West Roxbury VA Hospital/Harvard Medical School, West Roxbury, MA 02132. Courtney Holmes Clinical Neurocardiology Section, National Institute of Neurological Disease and Stroke, Bethesda, MD 20892. Qingsheng Gao Department of Neurology, West Roxbury VA Hospital/Harvard Medical School, West Roxbury, MA 02132. Guo-Rong Zhang Department of Neurology, West Roxbury VA Hospital/Harvard Medical School, West Roxbury, MA 02132. Josef Pfeilschifter Pharmazentrum Frankfurt, University Hospital, 60590 Frankfurt, Germany. David S. Goldstein Clinical Neurocardiology Section, National Institute of Neurological Disease and Stroke, Bethesda, MD 20892. Dr. Alfred I. Geller Department of Neurology, West Roxbury VA Hospital/Harvard Medical School, West Roxbury, MA 02132. Parkinson's disease is due to the selective loss of nigrostriatal dopaminergic neurons. Consequently, many therapeutic strategies have focused on restoring striatal dopamine levels, including direct gene transfer to striatal cells, using viral vectors that express specific dopamine biosynthetic enzymes. The central hypothesis of this study is that coexpression of four dopamine biosynthetic and transporter genes in striatal neurons can support the efficient production and regulated, vesicular release of dopamine: tyrosine hydroxylase (TH) converts tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), GTP cyclohydrolase I (GTP CH I) is the rate-limiting enzyme in the biosynthesis of the cofactor for TH, aromatic amino acid decarboxylase (AADC) converts L-DOPA to dopamine, and a vesicular monoamine transporter (VMAT-2) transports dopamine into synaptic vesicles, thereby supporting regulated, vesicular release of dopamine and relieving feedback inhibition of TH by dopamine. Helper virus-free herpes simplex virus type 1 vectors that coexpress the three dopamine biosynthetic enzymes (TH, GTP CH I, and AADC; 3-gene-vector) or these three dopamine biosynthetic enzymes and the vesicular monoamine transporter (TH, GTP CH I, AADC, and VMAT-2; 4-gene-vector) were compared. Both vectors supported production of dopamine in cultured fibroblasts. These vectors were microinjected into the striatum of 6-hydroxydopamine-lesioned rats. These vectors carry a modified neurofilament gene promoter, and γ-aminobutyric acid (GABA)-ergic neuron-specific gene expression was maintained for 14 months after gene transfer. The 4-gene-vector supported higher levels of correction of apomorphine-induced rotational behavior than did the 3-gene-vector, and this correction was maintained for 6 months. Proximal to the injection sites, the 4-gene-vector, but not the 3-gene-vector, supported extracellular levels of dopamine and dihydroxyphenylacetic acid (DOPAC) that were similar to those observed in normal rats, and only the 4-genevector supported significant K+-dependent release of dopamine.  This paper was cited by:Improved spatial learning in aged rats by genetic activation of protein kinase C in small groups of hippocampal neurons Guo-rong Zhang, Meng Liu, Haiyan Cao, Lingxin Kong, Xiaodan Wang, Jennifer A. O'Brien, Shuo-chieh Wu, Robert G. Cook, Alfred I. Geller Hippocampus. Jun 2009, Vol. 19, No. 5: 413-423 CrossRef Stable Transgene Expression From HSV Amplicon Vectors in the Brain: Potential Involvement of Immunoregulatory Signals Masataka Suzuki, E. Antonio Chiocca, Yoshinaga Saeki Molecular Therapy. Nov 2008, Vol. 16, No. 10: 1727-1736 CrossRef HSV-1 amplicon vectors Delphine Cuchet, Corinne Potel, Joélle Thomas, Alberto L Epstein Expert Opinion on Biological Therapy. Aug 2007, Vol. 7, No. 7: 975-995 CrossRef Spatial And Temporal Expression of Herpes Simplex Virus Type 1 Amplicon-Encoded Genes: Implications for Their Use As Immunization Vectors Kathlyn Santos, David A.L. Simon, Erin Conway, William J. Bowers, Soumya Mitra, Thomas H. Foster, Amit Lugade, Edith M. Lord, Howard J. Federoff, Stephen Dewhurst, John G. Frelinger Human Gene Therapy. Feb 2007, Vol. 18, No. 2: 93-105 Abstract | Full Text PDF | Reprints & PermissionsTransduction of Brain by Herpes Simplex Virus Vectors Bradford K Berges, John H Wolfe, Nigel W Fraser Molecular Therapy. Feb 2007, Vol. 15, No. 1: 20-29 CrossRef Human gene therapy and imaging in neurological diseases Andreas H. Jacobs, Alexandra Winkler, Maria G. Castro, Pedro Lowenstein European Journal of Nuclear Medicine and Molecular Imaging. Jan 2006, Vol. 32, No. S02: S358-S383 CrossRef Effect of Solution Composition of Plasmid DNA on Gene Transfection Following Liver Surface Administration in Mice Ryu Hirayama, Shintaro Fumoto, Koyo Nishida, Mikiro Nakashima, Hitoshi Sasaki, Junzo Nakamura Biological & Pharmaceutical Bulletin. Feb 2005, Vol. 28, No. 11: 2166-2169 CrossRef
|
|